Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib-Reference-Cited by-同舟云学术

Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib

Published:2018-09-02 Issue:4 Volume:183 Page:578-587
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Jain Preetesh¹²^ORCID,Kanagal-Shamanna Rashmi³,Zhang Shaojun⁴,Ahmed Makhdum⁵,Ghorab Ahmad⁵,Zhang Liang¹,Ok Chi Young³,Li Shaoying³,Hagemeister Frederick¹,Zeng Dongfeng¹,Gong Tiejun¹,Chen Wendy¹,Badillo Maria¹,Nomie Krystle¹,Fayad Luis¹,Medeiros Leonard J.³,Neelapu Sattva¹,Fowler Nathan¹,Romaguera Jorge¹^ORCID,Champlin Richard⁶,Wang Linghua⁴,Wang Michael L.¹

Affiliation:

1. Department of Lymphoma and Myeloma; the University of Texas MD Anderson Cancer Center; Houston TX USA

2. Division of Cancer Medicine; the University of Texas MD Anderson Cancer Center; Houston TX USA

3. Department of Hematopathology; the University of Texas MD Anderson Cancer Center; Houston TX USA

4. Department of Genomic Medicine; the University of Texas MD Anderson Cancer Center; Houston TX USA

5. Department of Leukemia; the University of Texas MD Anderson Cancer Center; Houston TX USA

6. Department of Stem cell transplant; the University of Texas MD Anderson Cancer Center; Houston TX USA

Funder

MD Anderson Cancer Center B Cell Lymphoma Moon Shot Program

Gary Rogers Foundation

Fox Family Foundation

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.15567/fullpdf

Reference32 articles.

1. Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia;Ahn;Blood,2017

2. Expression of TP53 is associated with outcome of MCL independent of MIPI and Ki-67 in trials of the European-MCL network;Aukema;Blood,2018

3. Is there an increased rate of additional malignancies in patients with mantle cell lymphoma?;Barista;Annals of Oncology,2002

4. Landscape of somatic mutations and clonal evolution in mantle cell lymphoma;Bea;Proceedings of the National Academy of Sciences of the United States of America,2013

5. Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition;Burger;Nature Communications,2016

Cited by 78 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Genetic and prognostic analysis of blastoid and pleomorphic mantle cell lymphoma: a multicenter analysis in China;Annals of Hematology;2024-01-02

2. Lisocabtagene Maraleucel in Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis of the Mantle Cell Lymphoma Cohort From TRANSCEND NHL 001, a Phase I Multicenter Seamless Design Study;Journal of Clinical Oncology;2023-12-10

3. Predictive and prognostic molecular biomarkers in lymphomas;Pathology;2023-12

4. Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma;Leukemia & Lymphoma;2023-10-16

5. PRMT5 inhibition drives therapeutic vulnerability to combination treatment with BCL-2 inhibition in mantle cell lymphoma;Blood Advances;2023-10-13